Title: PI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide.
Journal: PloS one 20160101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Journal: The Biochemical journal 20130415
Title: Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration.
Journal: The international journal of biochemistry & cell biology 20121101
Title: PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
Journal: Journal of medicinal chemistry 20121025
Title: A yeast-based in vivo bioassay to screen for class I phosphatidylinositol 3-kinase specific inhibitors.
Journal: Journal of biomolecular screening 20120901
Title: Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Journal: Breast cancer research and treatment 20120901
Title: Reconciling the different roles of Gsk3β in 'naïve' and 'primed' pluripotent stem cells.
Journal: Cell cycle (Georgetown, Tex.) 20120815
Title: PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Journal: The Journal of surgical research 20120801
Title: Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Journal: Bioscience reports 20120801
Title: Inhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxide.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20120701
Title: The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Journal: Anticancer research 20120701
Title: A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.
Journal: Nature chemical biology 20120429
Title: Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Journal: The Journal of biological chemistry 20120406
Title: Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Journal: Molecular cancer research : MCR 20120301
Title: Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo.
Journal: The Biochemical journal 20120215
Title: Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
Journal: Anticancer research 20120201
Title: Current development of the second generation of mTOR inhibitors as anticancer agents.
Journal: Chinese journal of cancer 20120101
Title: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Journal: Cancer biology & therapy 20120101
Title: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.
Journal: BMC biology 20120101
Title: PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
Journal: PloS one 20120101
Title: Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
Journal: International journal of cancer 20111215
Title: GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
Journal: The Journal of clinical endocrinology and metabolism 20111201
Title: Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
Journal: Bioorganic & medicinal chemistry 20111115
Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Journal: Carcinogenesis 20111001
Title: 5-Methoxyflavanone induces cell cycle arrest at the G2/M phase, apoptosis and autophagy in HCT116 human colon cancer cells.
Journal: Toxicology and applied pharmacology 20110801
Title: Differential regulation of CIDEA and CIDEC expression by insulin via Akt1/2- and JNK2-dependent pathways in human adipocytes.
Journal: Journal of lipid research 20110801
Title: Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
Journal: Cancer research 20110701
Title: PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.
Journal: American journal of physiology. Cell physiology 20110601
Title: Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Journal: European journal of medicinal chemistry 20110601
Title: Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
Journal: Neuro-oncology 20110601
Title: Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.
Journal: EMBO reports 20110501
Title: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110415
Title: Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Journal: European journal of medicinal chemistry 20110401
Title: Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
Journal: The Journal of investigative dermatology 20110201
Title: PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Journal: Oncogene 20110127
Title: Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor.
Journal: Oncogene 20110113
Title: A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.
Journal: Cancer research 20110101
Title: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
Journal: PloS one 20110101
Title: PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Journal: Anticancer research 20101201
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Akt and autophagy cooperate to promote survival of drug-resistant glioma.
Journal: Science signaling 20101109
Title: Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption.
Journal: British journal of pharmacology 20101001
Title: The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Journal: Cancer research 20100701
Title: Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601
Title: The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
Journal: International journal of cancer 20100401
Title: Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34.
Journal: Science (New York, N.Y.) 20100326
Title: Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Journal: Cancer research 20100315
Title: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Journal: Cancer research 20100201
Title: Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.
Journal: PloS one 20100101
Title: Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
Journal: The Journal of biological chemistry 20091009
Title: The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
Journal: Oncogene 20091008
Title: A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Journal: International journal of molecular medicine 20090701
Title: Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Journal: Molecular cancer therapeutics 20090701
Title: Inhibition of insulin-stimulated hydrogen peroxide production prevents stimulation of sodium transport in A6 cell monolayers.
Journal: American journal of physiology. Renal physiology 20090601
Title: Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
Journal: Anticancer research 20090601
Title: Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Journal: Blood 20090528
Title: Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses.
Journal: Cancer research 20090501
Title: Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Journal: Molecular cancer therapeutics 20090501
Title: Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Journal: Cancer research 20090415
Title: Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Journal: Cancer research 20090201
Title: Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Journal: Cell cycle (Georgetown, Tex.) 20090201
Title: Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Journal: Biological & pharmaceutical bulletin 20090201
Title: High-throughput screening compatible cell-based assay for interrogating activated notch signaling.
Journal: Assay and drug development technologies 20090201
Title: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
Journal: Nature chemical biology 20081101
Title: Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Journal: Cancer research 20081015
Title: Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
Journal: The Journal of allergy and clinical immunology 20081001
Title: The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
Journal: Leukemia 20080901
Title: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Journal: Leukemia 20080901
Title: PDGF- and insulin/IGF-1-specific distinct modes of class IA PI 3-kinase activation in normal rat retinas and RGC-5 retinal ganglion cells.
Journal: Investigative ophthalmology & visual science 20080801
Title: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Journal: Cancer research 20080715
Title: Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Journal: Molecular cancer therapeutics 20080401
Title: A quantitative analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20080101
Title: A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20071218
Title: The selectivity of protein kinase inhibitors: a further update.
Journal: The Biochemical journal 20071215
Title: Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Journal: Bioorganic & medicinal chemistry 20070901
Title: A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Journal: Cancer research 20070901
Title: Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20070501
Title: A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.
Journal: Cell 20060519
Title: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
Journal: Cancer cell 20060501
Title: Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39.
Title: Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47.
Title: Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706.
Title: López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61.
